EGF-Containing Membrane-Bound Mucins: A Hidden ErbB2 Targeting Pathway?
Maxime LiberelleNicolas JonckheerePatricia MelnykIsabelle Van SeuningenNicolas LebeguePublished in: Journal of medicinal chemistry (2020)
Membrane-bound mucins belong to a heterogeneous family of large O-glycoproteins involved in numerous cancers and inflammatory diseases of the epithelium. Some of them are also involved in protein-protein interactions, with receptor tyrosine kinase ErbB2, and fundamental and clinical data showed that these complexes have a detrimental impact on cancer outcome, thus raising interest in therapeutic targeting. This paper aims to demonstrate that MUC3, MUC4, MUC12, MUC13, and MUC17 have a common evolutionary origin and share a common structural organization with EGF-like and SEA domains. Theoretical structure-function relationship analysis of the conserved domains indicated that the studied membrane-bound mucins share common biological properties along with potential specific functions. Finally, the potential druggability of these complexes is discussed, revealing ErbB2-related pathways of cell signaling to be targeted.
Keyphrases
- tyrosine kinase
- epidermal growth factor receptor
- protein protein
- cancer therapy
- small molecule
- growth factor
- single cell
- cell therapy
- stem cells
- squamous cell carcinoma
- papillary thyroid
- transcription factor
- gene expression
- climate change
- squamous cell
- mesenchymal stem cells
- machine learning
- genome wide
- dna methylation
- drug induced
- lymph node metastasis